Drugs / attIL12-TIL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06474676 | Sep 2025 → Dec 2030 expected | soft tissue sarcoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | attIL12-TIL | “T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL)” NCT06474676 ↗ |
| Modality | Cell therapy | “TIL Cell Therapy” NCT06474676 ↗ |
| Route | Intravenous | “Given by IV” NCT06474676 ↗ |